Results 21 to 30 of about 13,061,190 (344)

Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells

Frontiers in Immunology, 2020
The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients. Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on ...
Sandrine Delignat, Julie Rayes, Suryasarathi Dasgupta, Bagirath Gangadharan, Cécile V. Denis, Olivier D. Christophe, Jagadeesh Bayry, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +8 more
doaj   +1 more source

High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor

Journal of Thrombosis and Haemostasis, 2018
Essentials Elevated procoagulant levels are associated with an increased risk of venous thrombosis (VT). The dependency on concurrent increased factor levels and VT was analyzed in a large study.
I. M. Rietveld, W. Lijfering, S. Cessie, M. Bos, F. Rosendaal, P. Reitsma, S. Cannegieter   +6 more
semanticscholar   +1 more source

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII

Journal of Thrombosis and Haemostasis, 2017
Essentials Recombinant factor VIII BAY 94‐9027 conjugates in a site‐specific manner with polyethylene glycol. BAY 94‐9027 was given to patients with severe hemophilia A as prophylaxis and to treat bleeds. BAY 94‐9027 prevented bleeds at dose intervals up
M. Reding, Heng Joo Ng, L. Poulsen, M. E. Eyster, Ingrid Pabinger, H. J. Shin, R. Walsch, Michael M. Lederman, Maria Wang, M. Hardtke, Lisa A. Michaels   +10 more
semanticscholar   +1 more source

Acquired Factor VIII Deficiency Presenting as Gross Hematuria in a Hispanic, Pregnant Patient with Previously Undiagnosed Connective Tissue Disease

Case Reports in Rheumatology, 2021
Acquired factor VIII deficiency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deficiency
Christine Loftis, Emilia C. Dulgheru, Rosa White   +2 more
doaj   +1 more source

Calcium Prevents Enhanced Degradation of Factor VIII in the Condition of Motion

Biology, 2023
Background: Hemophilia A and B induce recurrent bleeding episodes, mainly in skeletal muscles and joints that are in intermittent motion. We have previously demonstrated that intermittent motion contributes to increased degradation of factors VIII and IX.
Haim Cohen, Anat Keren-Politansky, Yonatan Crispel, Chen Yanovich, Keren Asayag, Yona Nadir   +5 more
doaj   +1 more source

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII

Molecular Therapy: Methods & Clinical Development, 2020
It is well known that canine factor VIII (cFVIII) has a higher specific activity than does human FVIII (hFVIII), and it has been previously demonstrated that cFVIII light chain is able to enhance hFVIII activity.
Jenni Firrman, Qizhao Wang, Wenman Wu, Biao Dong, Wenjing Cao, Andrea Rossi Moore, Sean Roberts, Barbara A. Konkle, Carol Miao, LinShu Liu, Dong Li, Weidong Xiao   +11 more
doaj   +1 more source

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021

Research and Practice in Thrombosis and Haemostasis, 2021
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products.
Yesim Dargaud, Carmen Escuriola‐Ettingshausen   +1 more
doaj   +1 more source

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Haematologica, 2019
Therapeutic factor VIII is highly immunogenic. Despite intensive research in the last decades, the reasons why 5-30% of patients with hemophilia A (of all severities) develop inhibitory anti-factor VIII antibodies (inhibitors) following replacement ...
Aditi Varthaman, Sébastien Lacroix-Desmazes   +1 more
doaj   +1 more source

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +1 more source

Factor VIII/V C-domain swaps reveal discrete C-domain roles in factor VIII function and intracellular trafficking

Haematologica, 2017
Factor VIII C-domains are believed to have specific functions in cofactor activity and in interactions with von Willebrand factor. We have previously shown that factor VIII is co-targeted with von Willebrand factor to the Weibel-Palade bodies in blood ...
Eduard H.T.M. Ebberink, Eveline A.M. Bouwens, Esther Bloem, Mariëtte Boon-Spijker, Maartje van den Biggelaar, Jan Voorberg, Alexander B. Meijer, Koen Mertens   +7 more
doaj   +1 more source